CpG Island Methylator Phenotype and Prognosis of Colorectal Cancer in Northeast China

BioMed Research International

Volumn 2014, Issue , 2014, Pages

  Li, Xia ^a   Hu, Fulan ^a   Wang, Yibaina ^a   Yao, Xiaoping ^a   Zhang, Zuoming ^a   Wang, Fan ^a   Sun, Guizhi ^a   Cui, Bin Bin ^a   Dong, Xinshu ^a   Zhao, Yashuang ^a  

^a HARBIN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

APC PROTEIN; FLUOROURACIL; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; MINT1 PROTEIN; MINT31 PROTEIN; PROTEIN; PROTEIN MLH1; PROTEIN P16; TRANSCRIPTION FACTOR RUNX3; UNCLASSIFIED DRUG;

ADJUVANT CHEMOTHERAPY; ADULT; ADVERSE OUTCOME; AGED; ARTICLE; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHINA; COLORECTAL CANCER; CPG ISLAND; DNA METHYLATION; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PREDICTIVE VALUE; PROMOTER REGION; TUMOR DIFFERENTIATION; COLORECTAL TUMOR; GENETICS; MIDDLE AGED; PATHOLOGY; PHENOTYPE; PROGNOSIS; SURVIVAL ANALYSIS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CHINA; COLORECTAL NEOPLASMS; CPG ISLANDS; DNA METHYLATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PHENOTYPE; PROGNOSIS; PROMOTER REGIONS, GENETIC; SURVIVAL ANALYSIS;

EID: 84921869038     PISSN: 23146133     EISSN: 23146141     Source Type: Journal    
DOI: 10.1155/2014/236361     Document Type: Article

References (68)

1. C. C. Compton, "Colorectal carcinoma: diagnostic, prognostic, and molecular features, " Modern Pathology, vol. 16, no. 4, pp. 376-388, 2003.
2. http://globocan.iarc.fr/Pages/fact-sheets-cancer.aspx
3. M. P. Coleman, D. Forman, H. Bryant et al., "Cancer survival in Australia, Canada, Denmark, Norway, Sweden, and the UK, 1995-2007 (the International Cancer Benchmarking Partnership): an analysis of population-based cancer registry data, " The Lancet, vol. 377, no. 9760, pp. 127-138, 2011.
4. M. P. Coleman, M. Quaresma, F. Berrino et al., "Cancer survival in five continents: a worldwide population-based study (CONCORD), " The Lancet Oncology, vol. 9, no. 8, pp. 730-756, 2008.
5. L. Shen, P. J. Catalano, A. B. Benson III, P. ODwyer, S. R. Hamilton, and J. J. Issa, "Association between DNAmethylation and shortened survival in patients with advanced colorectal cancer treated with 5-fluorouracil-based chemotherapy, " Clinical Cancer Research, vol. 13, no. 20, pp. 6093-6098, 2007.
6. M. van Rijnsoever, H. Elsaleh, D. Joseph, K. McCaul, and B. Iacopetta, "CpG island methylator phenotype is an independent predictor of survival benefit from 5-fluorouracil in stage III colorectal cancer, " Clinical Cancer Research, vol. 9, no. 8, pp. 2898-2903, 2003.
7. S. Ogino and A. Goel, "Molecular classification and correlates in colorectal cancer, " Journal of Molecular Diagnostics, vol. 10, no. 1, pp. 13-27, 2008.
8. W. M. Grady and J. M. Carethers, "Genomic and epigenetic instability in colorectal cancer pathogenesis, " Gastroenterology, vol. 135, no. 4, pp. 1079-1099, 2008.
9. J. Issa, "CpG island methylator phenotype in cancer, " Nature Reviews Cancer, vol. 4, no. 12, pp. 988-993, 2004.
10. J. R. Jass, "Classification of colorectal cancer based on correlation of clinical, morphological and molecular features, " Histopathology, vol. 50, no. 1, pp. 113-130, 2007.
11. S. Popat, R. Hubner, and R. S. Houlston, "Systematic review of microsatellite instability and colorectal cancer prognosis, " Journal of Clinical Oncology, vol. 23, no. 3, pp. 609-618, 2005.
12. L. Barault, C. Charon-Barra, V. Jooste et al., "Hypermethylator phenotype in sporadic colon cancer: study on a populationbased series of 582 cases, " Cancer Research, vol. 68, no. 20, pp. 8541-8546, 2008.
13. J. B. Ahn, W. B. Chung, O. Maeda et al., "DNA methylation predicts recurrence from resected stage III proximal colon cancer, " Cancer, vol. 117, no. 9, pp. 1847-1854, 2011.
14. A. M. Dahlin, R. Palmqvist, M. L. Henriksson et al., "The role of the CpG island methylator phenotype in colorectal cancer prognosis depends on microsatellite instability screening status, " Clinical Cancer Research, vol. 16, no. 6, pp. 1845-1855, 2010.
15. Y. Rhee, M. J. Kim, J. M. Bae et al., "Clinical outcomes of patients with microsatellite-unstable colorectal carcinomas depend on l1 methylation level, " Annals of SurgicalOncology, vol. 19, no. 11, pp. 3441-3448, 2012.
16. P. Jo, K. Jung, M. Grade et al., "CpG island methylator phenotype infers a poor disease-free survival in locally advanced rectal cancer, " Surgery, vol. 151, no. 4, pp. 564-570, 2012.
17. J. M. Bae, J. H. Kim, N. Y. Cho, T. Kim, and G. H. Kang, "Prognostic implication of the CpG island methylator phenotype in colorectal cancers depends on tumour location, " British Journal of Cancer, vol. 109, no. 4, pp. 1004-1012, 2013.
18. W. S. Samowitz, K. Curtin, R. K. Wolff, S. R. Tripp, B. J. Caan, and M. L. Slattery, "Microsatellite instability and survival in rectal cancer, " Cancer Causes and Control, vol. 20, no. 9, pp. 1763-1768, 2009.
19. J. H. Kim, S. H. Shin, H. J. Kwon, N. Y. Cho, and G. H. Kang, "Prognostic implications of CpG island hypermethylator phenotype in colorectal cancers, " Virchows Archiv, vol. 455, no. 6, pp. 485-494, 2009.
20. S. Lee, N. Cho, M. Choi, E. J. Yoo, J. Kim, and G. H. Kang, "Clinicopathological features of CpG island methylator phenotype-positive colorectal cancer and its adverse prognosis in relation to KRAS/BRAF mutation, " Pathology International, vol. 58, no. 2, pp. 104-113, 2008.
21. M. Ferracin, R. Gafa, E. Miotto et al., "The methylator phenotype in microsatellite stable colorectal cancers is characterized by a distinct gene expression profile, " Journal of Pathology, vol. 214, no. 5, pp. 594-602, 2008.
22. J. A. Sanchez, L. Krumroy, S. Plummer et al., "Genetic and epigenetic classifications define clinical phenotypes and determine patient outcomes in colorectal cancer, " British Journal of Surgery, vol. 96, no. 10, pp. 1196-1204, 2009.
23. S. Kakar, G. Deng, V. Sahai et al., "Clinicopathologic characteristics, CpG island methylator phenotype, and BRAF mutations in microsatellite-stable colorectal cancers without chromosomal instability, " Archives of Pathology and Laboratory Medicine, vol. 132, no. 6, pp. 958-964, 2008.
24. R. Jover, T. Nguyen, L. Prezcarbonell et al., "5-fluorouracil adjuvant chemotherapy does not increase survival in patients with CpG island methylator phenotype colorectal cancer, " Gastroenterology, vol. 140, no. 4, pp. 1174-1181, 2011.
25. M. Donada, S. Bonin, R. Barbazza, D. Pettirosso, and G. Stanta, "Management of stage II colon cancer-the use of molecular biomarkers for adjuvant therapy decision, " BMC Gastroenterology, vol. 13, article 36, 2013.
26. S. Han, H. Lee, J. M. Bae et al., "Methylation and microsatellite status and recurrence following adjuvant FOLFOX in colorectal cancer, " International Journal of Cancer, vol. 132, no. 9, pp. 2209-2216, 2013.
27. B. Min, J. M. Bae, E. J. Lee et al., "The CpG island methylator phenotypemay confer a survival benefit in patients with stage II or III colorectal carcinomas receiving fluoropyrimidine-based adjuvant chemotherapy, " BMC Cancer, vol. 11, article 344, 2011.
28. W. S. Samowitz, C. Sweeney, J. Herrick et al., "Poor survival associated with the BRAF V600E mutation in microsatellitestable colon cancers, " Cancer Research, vol. 65, no. 14, pp. 6063-6070, 2005.
29. M. R. Kohonen-Corish, J. Tseung, and C. Chan, "KRAS mutations and CDKN2A promoter methylation show an interactive adverse effect on survival and predict recurrence of rectal cancer, " International Journal of Cancer, vol. 134, no. 12, pp. 2820-2828, 2014.
30. J. H. Kim, Y. Y. Rhee, J. M. Bae, N. Y. Cho, andG. H. Kang, "Loss of CDX2/CK20 expression is associated with poorly differentiated carcinoma, the CpG island methylator phenotype, and adverse prognosis in microsatellite-unstable colorectal cancer, " The American Journal of Surgical Pathology, vol. 37, no. 10, pp. 1532-1541, 2013.
31. N. J. Samadder, R. A. Vierkant, L. S. Tillmans et al., "Associations between colorectal cancer molecular markers and pathways with clinicopathologic features in older women, " Gastroenterology, vol. 145, no. 2, pp. 348-356, 2013.
32. R. L. Ward, K. Cheong, S. L. Ku, A. Meagher, T. OConnor, and N. J. Hawkins, "Adverse prognostic effect of methylation in colorectal cancer is reversed by microsatellite instability, " Journal of ClinicalOncology, vol. 21, no. 20, pp. 3729-3736, 2003.
33. S. Ogino, K. Nosho, G. J. Kirkner et al., "CpG island methylator phenotype, microsatellite instability, BRAF mutation and clinical outcome in colon cancer, " Gut, vol. 58, no. 1, pp. 90-96, 2009.
34. L. H. Sobin and I. D. Fleming, "TNM Classification of Malignant Tumors, fifth edition (1997). Union Internationale Contre le Cancer and the American Joint Committee on Cancer, " Cancer, vol. 80, no. 9, pp. 1803-1804, 1997.
35. S. R. Hamilton and L. A. Aaltonen, World Health Organization Classification of Tumours. Pathology and Genetics of Tumours of Digestive System, IARC Press, Lyon, France, 2000.
36. D. J. Weisenberger, K. D. Siegmund, M. Campan et al., "CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer, " Nature Genetics, vol. 38, no. 7, pp. 787-793, 2006.
37. L. A. E. Hughes, C. A. J. Khalid-de Bakker, K. M. Smits et al., "The CpG island methylator phenotype in colorectal cancer: progress and problems, " Biochimica et Biophysica Acta-Reviews on Cancer, vol. 1825, no. 1, pp. 77-85, 2012.
38. A. Goel, T. Nagasaka, C. N. Arnold et al., "The CpG island methylator phenotype and chromosomal instability are inversely correlated in sporadic colorectal cancer, " Gastroenterology, vol. 132, no. 1, pp. 127-138, 2007.
39. S. Ogino, J. A. Meyerhardt, T. Kawasaki et al., "CpG island methylation, response to combination chemotherapy, and patient survival in advanced microsatellite stable colorectal carcinoma, " Virchows Archiv, vol. 450, no. 5, pp. 529-537, 2007.
40. T. Hinoue, D. J. Weisenberger, C. P. E. Lange et al., "Genomescale analysis of aberrant DNA methylation in colorectal cancer, " Genome Research, vol. 22, no. 2, pp. 271-282, 2012.
41. K. Bardhan and K. Liu, "Epigenetics and colorectal cancer pathogenesis, " Cancers, vol. 5, no. 2, pp. 676-713, 2013.
42. Y. S. Kim and G. Deng, "Epigenetic changes (aberrant DNA methylation) in colorectal neoplasia, " Gut Liver, vol. 1, no. 1, pp. 1-11, 2007.
43. D. Colussi, G. Brandi, and F. Bazzoli, "Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention, " International Journal ofMolecular Sciences, vol. 14, no. 8, pp. 16365-16385, 2013.
44. S. Ogino, A. T. Chan, C. S. Fuchs, and E. Giovannucci, "Molecular pathological epidemiology of colorectal neoplasia: an emerging transdisciplinary and interdisciplinary field, " Gut, vol. 60, no. 3, pp. 397-411, 2011.
45. K. Curtin, M. L. Slattery, and W. S. Samowitz, "CpG island methylation in colorectal cancer: past, present and future, " Pathology Research International, vol. 2011, Article ID 902674, pages, 2011.
46. J. H. Kim and G. H. Kang, "Molecular and prognostic heterogeneity of microsatellite-unstable colorectal cancer, " World Journal of Gastroenterology, vol. 20, no. 15, pp. 4230-4243, 2014.
47. A. E. Noffsinger, "Serrated polyps and colorectal cancer: new pathway tomalignancy, " Annual Review of Pathology, vol. 4, pp. 343-364, 2009.
48. D. C. Snover, "Update on the serrated pathway to colorectal carcinoma, " Human Pathology, vol. 42, no. 1, pp. 1-10, 2011.
49. M. Toyota, N. Ahuja, M. Ohe-Toyota, J. G. Herman, S. B. Baylin, and J. J. Issa, "CpG island methylator phenotype in colorectal cancer, " Proceedings of the National Academy of Sciences of the United States of America, vol. 96, no. 15, pp. 8681-8686, 1999.
50. P. A. Jones and S. B. Baylin, "The fundamental role of epigenetic events in cancer, " Nature Reviews Genetics, vol. 3, no. 6, pp. 415-428, 2002.
51. I. J. H. van Vlodrop, H. E. C. Niessen, S. Derks et al., "Analysis of promoter CpG island hypermethylation in cancer: location, location, location!, " Clinical Cancer Research, vol. 17, no. 13, pp. 4225-4231, 2011.
52. T. K. Wojdacz, A. Dobrovic, and L. L. Hansen, "Methylationsensitive high-resolution melting, " Nature Protocols, vol. 3, no. 12, pp. 1903-1908, 2008.
53. W. Meng, A. Huebner, A. Shabsigh, A. Chakravarti, and T. Lautenschlaeger, "Combined RASSF1A and RASSF2A promotermethylation analysis as diagnostic biomarker for bladder cancer, " Molecular Biology International, vol. 2012, Article ID 701814, 8 pages, 2012.
54. M. Balic, M. Pichler, J. Strutz et al., "High quality assessment of DNA methylation in archival tissues from colorectal cancer patients using quantitative high-resolution melting analysis, " Journal ofMolecularDiagnostics, vol. 11, no. 2, pp. 102-108, 2009.
55. L. Morandi, E. Franceschi, D. de Biase et al., "Promoter methylation analysis ofO6-methylguanine-DNAmethyltransferase in glioblastoma: detection by locked nucleic acid based quantitative PCR using an imprinted gene (SNURF) as a reference, " BMC Cancer, vol. 10, article 48, 2010.
56. A. Avraham, R. Uhlmann, A. Shperber et al., "Serum DNA methylation for monitoring response to neoadjuvant chemotherapy in breast cancer patients, " International Journal of Cancer, vol. 131, no. 7, pp. E1166-E1172, 2012.
57. L. S. Kristensen, T. Mikeska, M. Krypuy, and A. Dobrovic, "Sensitive melting analysis after real time-methylation specific PCR (SMART-MSP): high-throughput and probe-free quantitative DNAmethylation detection, "Nucleic Acids Research, vol. 36, no. 7, article e42, 2008.
58. S. Ogino, T. Kawasaki, G. J. Kirkner, M. Loda, and C. S. Fuchs, "CpG island methylator phenotype-low (CIMP-low) in colorectal cancer: possible associationswithmale sex andKRAS mutations, " Journal of Molecular Diagnostics, vol. 8, no. 5, pp. 582-588, 2006.
59. K. Nosho, N. Irahara, K. Shima et al., "Comprehensive biostatistical analysis of CpG island methylator phenotype in colorectal cancer using a large population-based sample, " PLoS ONE, vol. 3, no. 11, Article ID e3698, 2008.
60. S. Ogino, T. Kawasaki, G. J. Kirkner, Y. Suemoto, J. A. Meyerhardt, and C. S. Fuchs, "Molecular correlates with MGMT promoter methylation and silencing supportCpGislandmethylator phenotype-low (CIMP-low) in colorectal cancer, " Gut, vol. 56, no. 11, pp. 1564-1571, 2007.
61. T. Kawasaki, M. Ohnishi, K. Nosho et al., "CpG island methylator phenotype-low (CIMP-low) colorectal cancer shows not only few methylated CIMP-high-specific CpG islands, but also low-levelmethylation at individual loci, " Modern Pathology, vol. 21, no. 3, pp. 245-255, 2008.
62. M. Esteller, A. Sparks, M. Toyota et al., "Analysis of adenomatous polyposis coli promoter hypermethylation in human cancer, " Cancer Research, vol. 60, no. 16, pp. 4366-4371, 2000.
63. M. O. Hiltunen, L. Alhonen, J. Koistinaho et al., "Hypermethylation of the APC (adenomatous polyposis coli) gene promoter region in human colorectal carcinoma, " International Journal of Cancer, vol. 70, no. 6, pp. 644-648, 1997.
64. S. Chen, S. Chiu, C. Wu et al., "The association of methylation in the promoter of APC and MGMT and the prognosis of Taiwanese CRC patients, " Genetic Testing and Molecular Biomarkers, vol. 13, no. 1, pp. 67-71, 2009.
65. J. G. Herman, J. R. Graff, S. Myohanen, B. D. Nelkin, and S. B. Baylin, "Methylation-specific PCR: a novel PCR assay for methylation status of CpG islands, " Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 18, pp. 9821-9826, 1996.
66. S. Lee, N. Cho, E. J. Yoo, J. H. Kim, and G. H. Kang, "CpG island methylator phenotype in colorectal cancers: comparison of the newand classicCPGislandmethylator phenotypemarker panels, " Archives of Pathology and LaboratoryMedicine, vol. 132, no. 10, pp. 1657-1665, 2008.
67. D. R. English, J. P. Young, J. A. Simpson et al., "Ethnicity and risk for colorectal cancers showing somatic BRAF V600E mutation or CpG island methylator phenotype, " Cancer Epidemiology Biomarkers and Prevention, vol. 17, no. 7, pp. 1774-1780, 2008.
68. J. C. Kim, J. S. Choi, S. A. Roh, D. H. Cho, T. W. Kim, and Y. S. Kim, "Promotermethylation of specific genes is associated with the phenotype and progression of colorectal adenocarcinomas, " Annals of Surgical Oncology, vol. 17, no. 7, pp. 1767-1776, 2010.